The news: TrumpRx, a website that connects patients to some discounted prescription medications, launched on Thursday night.

Here’s how it works: Consumers with prescriptions can buy TrumpRx medications at cash-pay discounted prices that were negotiated between the Trump administration and drugmakers.

So far, 16 of 17 Big Pharma companies struck deals with the government to lower drug prices after pressure from Trump. Among them, 5 pharmas have 43 medicines for a discount on TrumpRx. More drugs are expected to be on the website soon. Examples of lower-priced drugs on TrumpRx include popular GLP-1s like Wegovy (pill and injection), Zepbound, and Ozempic, EMD Serono’s fertility treatments, and medicines that treat high cholesterol and other common conditions.

Importantly, TrumpRx does not sell or dispense medications directly. It operates as a marketplace, providing coupons that consumers can take to a participating pharmacy to pay for the drug. When direct coupons aren’t available, patients are instead guided to a pharma company’s direct-to-consumer (D2C) website to purchase the drug.

Why it matters: TrumpRx will help a small cohort of people save on prescriptions, but most people are unlikely to benefit.

Insurance coverage for prescription drugs will almost always be cheaper than TrumpRx pricing. About 84% of US consumers under age 65 have prescription drug insurance coverage, per government data, and nearly everyone above age 65 is on Medicare.

TrumpRx discounts could help the uninsured or underinsured, but even those patients may still be unable to afford most TrumpRx prices.

• 82% of uninsured US adults ages 18 to 64 say it’s difficult to afford healthcare, per a January 2026 KFF poll.
• Despite being cheaper than prior manufacturer list prices, many TrumpRx drugs still run hundreds of dollars per prescription, beyond the reach of most cash-pay patients.

Implications for pharma companies: The coupon aspect of TrumpRx has the look and feel of GoodRx—only with far fewer drugs. TrumpRx otherwise serves just as an online hub that routes consumers to other channels to purchase their prescription medications, meaning it’s unclear what added value the site offers beyond showcasing drug discounts negotiated by the administration.

Still, for pharma companies—especially those selling drugs that are frequently uncovered by insurance—raising awareness of lower prices via TrumpRx could help them capture cash-pay demand. Roughly 80% of US consumers know little or nothing about the initiative, per a November 2025 KFF poll. Drugmakers that struck pricing deals with the White House are beginning to disclose modest financial hits from lower prices—losses they’ll need to offset by boosting prescription volume through campaigns that spotlight reduced pricing and online marketing that drives traffic to TrumpRx and their D2C websites.